Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

MultiCell Technologies Inc (EM) MCET

MultiCell Technologies, Inc., a biopharmaceutical company, develops novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and interventional cardiology and peripheral vessel applications. Its product portfolio comprises MCT-125, a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue; MCT-465, a preclinical synthetic double-stranded RNA (dsRNA) therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers; and MCT-485, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of various cancers. The company also develops Ideal BioStent, a bioabsorbable stent for interventional cardiology and peripheral vessel applications. MultiCell Technologies, Inc. has a license agreement with Corning Incorporated and Pfizer Inc. The company was formerly known as Exten Industries, Inc. and changed its name to MultiCell Technologies, Inc....


EXPM:MCET - Post by User

User Avatar Image
(0)
•••
  • MCETDREAMERX
Post by MCETDREAMERon Jun 30, 2021 7:34pm
139 Views
Post# 33477813

It is incomprehensible that MCET management refuses to file

It is incomprehensible that MCET management refuses to file It is incomprehensible that MCET management refuses to file with the SEC. It's ludicrous, that over 10 companies, one of which has 18 distributors around the world using MCETs Fa N2-4 patented intelligent properties. Then there is JCRB, a gigantic manufacturer of Fa N2-4 cell lines. And again, MCET management refuses to put a stop to it. This is complete incompetence, and criminal behavior by the directors, chairman and CEO, as they absolutely do nothing to prevent this from happening. This falls under neglect of fiduciary duties and responsibilities. And as shareholders, we can do something about it You just need to own stock. Or if you lost money. If you want to put a stop to this and make MCET management and any company that illegally sells MCET Fa N2-4 cell line and get Justice. It will be up to the attorney what we will ask for and who we go after, but I can assure you, we will make them pay for damages. And September 28 can come and go. Because, this attorney specializes in working with the SEC, and companies that neglects their fiduciary duties and responsibilities. They would like as much information as possible or that you're willing to give. Email: Name Phone Home address if possible? Email address How many shares you own. Please sign up here: mcetprephaseone@gmail.com Have a question? mcetdreamer@gmail.com Your information will be inputted with other names then sent to the attorney on a spreadsheet. Then after, all your information will be completely deleted after it's sent to the attorney.
<< Previous
Bullboard Posts